Impaired Glucose Tolerance in Healthy Men Treated with St. John's Wort

Basic & Clinical Pharmacology & Toxicology
Tore Bjerregaard StageKim Brøsen

Abstract

The purpose of this study was to examine whether the over-the-counter herbal medicinal plant St. John's wort affects glucose tolerance in healthy men. To do this, we included 10 healthy men who were examined by a 2-hr oral glucose tolerance test on three occasions: A: baseline; B: after 21 days of treatment with St. John's wort; and C: at least 6 weeks after the last capsule of St. John's wort was ingested. Plasma glucose, serum insulin and C-peptide levels were measured during an oral glucose tolerance test and used for estimation of area under the concentration-time curve (AUC) as well as indices of insulin sensitivity and insulin secretion. We found that treatment with St. John's wort increased total and incremental glucose AUC and 2-hr plasma glucose levels. Surprisingly, this effect was sustained and even further increased 6 weeks after the last capsule of St. John's wort was taken. No effect on indices of insulin sensitivity was seen, but indices of insulin secretion were reduced even after adjustment for insulin sensitivity. In conclusion, this study indicates that long-term treatment with St. John's wort may impair glucose tolerance by reducing insulin secretion in young, healthy men. The unregulated use of this over-th...Continue Reading

References

Jan 1, 1977·Acta diabetologica latina·B DrazninL Laurian
Sep 1, 1990·BMJ : British Medical Journal·J S YudkinA B Swai
Feb 17, 1972·The New England Journal of Medicine·C MalherbeP H Forsham
Feb 22, 2000·Lancet·F RuschitzkaG Noll
Jun 15, 2000·Proceedings of the National Academy of Sciences of the United States of America·L B MooreS A Kliewer
Aug 24, 2001·Pharmacopsychiatry·W E MüllerM Wonnemann
Feb 19, 2002·British Journal of Clinical Pharmacology·Martina HennessyJ Feely
Jul 15, 2003·Toxicological Sciences : an Official Journal of the Society of Toxicology·Lavinia CantoniSilvio Caccia
Sep 18, 2003·JAMA : the Journal of the American Medical Association·John S MarkowitzKenneth D Chavin
Dec 13, 2005·European Journal of Clinical Pharmacology·Silke C MuellerBernd Drewelow
Jan 2, 2007·Phytochemistry·Evangelos C TatsisIoannis P Gerothanassis
May 19, 2007·Planta medica·Chia-Hao ChenChun-Jung Lin
Jan 30, 2008·The International Journal of Biochemistry & Cell Biology·Marta MenegazziPellegrino Masiello
Aug 13, 2008·Analytical and Bioanalytical Chemistry·Ulrich M ZangerMatthias Schwab
Sep 3, 2008·European Journal of Clinical Pharmacology·Silke C MuellerBernd Drewelow
Nov 26, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Roja RahimiMohammad Abdollahi
Nov 26, 2010·Archives of Internal Medicine·An PanFrank B Hu
Dec 27, 2011·Biochimica Et Biophysica Acta·Allison J RichardJacqueline M Stephens
May 23, 2012·Expert Opinion on Drug Metabolism & Toxicology·Roja Rahimi, Mohammad Abdollahi
Apr 17, 2013·Clinical Pharmacology and Therapeutics·J RysäJ Hukkanen
Oct 30, 2013·Drug Metabolism and Drug Interactions·Janne HukkanenJaana Rysä
Sep 17, 2014·British Journal of Clinical Pharmacology·Tore Bjerregaard StageKim Brøsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.